AIMS/HYPOTHESIS: Immunological and genetic markers can be used to assess risk of developing type 1 diabetes prior to the onset of clinical symptoms. Autoantibody-positive relatives of patients with type 1 diabetes are at increased risk for disease, while the presence of HLA DQA1*0102/DQB1*0602 is thought to confer protection. Using the unique population identified by the Diabetes Prevention Trial--Type Diabetes (DPT-1), our aim was to determine if these individuals were protected from type 1 diabetes. METHODS: We described metabolic and immunological characteristics of islet cell cytoplasmic autoantibodies-positive relatives with DQB1*0602 identified as part of DPT-1. RESULTS: We found that 32% of DQB1*0602-positive relatives identified through the DPT-1 had abnormalities of glucose tolerance despite the fact that only 19% had multiple type 1 diabetes-associated autoantibodies and only 13% had abnormal insulin secretion, markers typically associated with the disease. In addition, these markers were not associated with abnormal glucose tolerance. In contrast, the DQB1*0602-positive relatives had elevated fasting insulin (117+/-10 pmol/l) and homeostasis model assessment of insulin resistance (HOMA-R) (4.90+/-0.5) values, which are more commonly associated with type 2 diabetes. The later marker of insulin resistance was associated with glucose tolerance status. CONCLUSIONS/ INTERPRETATION: Our data indicate that DQA1*0102/DQB1*0602 relatives identified through DPT-1 have a high frequency of abnormal glucose tolerance and a disease phenotype with characteristics of type 1 and type 2 diabetes. Thus, multiple pathways to abnormal glucose tolerance are present within families of these type 1 patients.
AIMS/HYPOTHESIS: Immunological and genetic markers can be used to assess risk of developing type 1 diabetes prior to the onset of clinical symptoms. Autoantibody-positive relatives of patients with type 1 diabetes are at increased risk for disease, while the presence of HLA DQA1*0102/DQB1*0602 is thought to confer protection. Using the unique population identified by the Diabetes Prevention Trial--Type Diabetes (DPT-1), our aim was to determine if these individuals were protected from type 1 diabetes. METHODS: We described metabolic and immunological characteristics of islet cell cytoplasmic autoantibodies-positive relatives with DQB1*0602 identified as part of DPT-1. RESULTS: We found that 32% of DQB1*0602-positive relatives identified through the DPT-1 had abnormalities of glucose tolerance despite the fact that only 19% had multiple type 1 diabetes-associated autoantibodies and only 13% had abnormal insulin secretion, markers typically associated with the disease. In addition, these markers were not associated with abnormal glucose tolerance. In contrast, the DQB1*0602-positive relatives had elevated fasting insulin (117+/-10 pmol/l) and homeostasis model assessment of insulin resistance (HOMA-R) (4.90+/-0.5) values, which are more commonly associated with type 2 diabetes. The later marker of insulin resistance was associated with glucose tolerance status. CONCLUSIONS/ INTERPRETATION: Our data indicate that DQA1*0102/DQB1*0602 relatives identified through DPT-1 have a high frequency of abnormal glucose tolerance and a disease phenotype with characteristics of type 1 and type 2 diabetes. Thus, multiple pathways to abnormal glucose tolerance are present within families of these type 1 patients.
Authors: T Lohmann; J Sessler; H J Verlohren; S Schröder; J Rötger; K Dãhn; N Morgenthaler; W A Scherbaum Journal: Diabetes Care Date: 1997-04 Impact factor: 19.112
Authors: M I Harris; K M Flegal; C C Cowie; M S Eberhardt; D E Goldstein; R R Little; H M Wiedmeyer; D D Byrd-Holt Journal: Diabetes Care Date: 1998-04 Impact factor: 19.112
Authors: J Graham; I Kockum; C B Sanjeevi; M Landin-Olsson; L Nyström; G Sundkvist; H Arnqvist; G Blohmé; F Lithner; B Littorin; B Scherstén; L Wibell; J Ostman; A Lernmark; N Breslow; G Dahlquist Journal: Eur J Immunogenet Date: 1999 Apr-Jun
Authors: V Horton; I Stratton; G F Bottazzo; M Shattock; I Mackay; P Zimmet; S Manley; R Holman; R Turner Journal: Diabetologia Date: 1999-05 Impact factor: 10.122
Authors: I Kockum; A Lernmark; G Dahlquist; A Falorni; W A Hagopian; M Landin-Olsson; L C Li; H Luthman; J P Palmer; C B Sanjeevi; G Sundkvist; I J Ostman Journal: Horm Metab Res Date: 1996-07 Impact factor: 2.936
Authors: S Caillat-Zucman; H J Garchon; J Timsit; R Assan; C Boitard; I Djilali-Saiah; P Bougnères; J F Bach Journal: J Clin Invest Date: 1992-12 Impact factor: 14.808
Authors: Jason L Gaglia; Alexander R Guimaraes; Mukesh Harisinghani; Stuart E Turvey; Richard Jackson; Christophe Benoist; Diane Mathis; Ralph Weissleder Journal: J Clin Invest Date: 2010-12-01 Impact factor: 14.808